Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3–18. https://doi.org/10.1136/ard-2022-223356.

Article  CAS  PubMed  Google Scholar 

de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57:1135–44. https://doi.org/10.1093/rheumatology/kex349.

Article  CAS  PubMed  Google Scholar 

Tan Y, Buch MH. Difficult to treat’ rheumatoid arthritis: current position and considerations for next steps. RMD Open. 2022;8:e002387. https://doi.org/10.1136/rmdopen-2022-002387.

Article  PubMed  PubMed Central  Google Scholar 

Buch MH. Defining refractory rheumatoid arthritis. Ann Rheum Dis. 2018;77:966–9. https://doi.org/10.1136/annrheumdis-2017-212862.

Article  CAS  PubMed  Google Scholar 

Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80:31–5. https://doi.org/10.1136/annrheumdis-2020-217344.

Article  PubMed  Google Scholar 

Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021;60:5247–56. https://doi.org/10.1093/rheumatology/keab209.

Article  CAS  PubMed  Google Scholar 

David P, Di Matteo A, Hen O, Dass S, Marzo-Ortega H, Wakefield RJ, et al. Poly-refractory rheumatoid arthritis: an uncommon subset of difficult to treat Disease with distinct inflammatory and noninflammatory phenotypes. Arthritis Rheumatol. 2024;76:510–21. https://doi.org/10.1002/art.42767.

Article  CAS  PubMed  Google Scholar 

Bertsias A, Flouri ID, Repa A, Avgoustidis N, Kalogiannaki E, Pitsigavdaki S, et al. Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with ‘difficult to treat’ rheumatoid arthritis. RMD Open. 2024;10:e003808. https://doi.org/10.1136/rmdopen-2023-003808.

Article  PubMed  PubMed Central  Google Scholar 

McDermott GC, DiIorio M, Kawano Y, Jeffway M, MacVicar M, Dahal K, et al. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis. Semin Arthritis Rheum. 2024;66:152421. https://doi.org/10.1016/j.semarthrit.2024.152421.

Article  CAS  PubMed  Google Scholar 

Watanabe R, Ebina K, Gon T, Okano T, Murata K, Murakami K, et al. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study. Rheumatology (Oxford). 2024;May 9(keae265). https://doi.org/10.1093/rheumatology/keae265.

Paudel ML, Li R, Naik C, Shadick N, Weinblatt ME, Solomon DH. Prevalence and characteristics of adults with difficult-to-treat rheumatoid arthritis in a large patient Registry. Rheumatol (Oxford) 2024 Jun 5:keae318. https://doi.org/10.1093/rheumatology/keae318

Smolen JS. Treat to target in Rheumatology: a historical account on occasion of the 10th anniversary. Rheum Dis Clin North Am. 2019;45:477–85. https://doi.org/10.1016/j.rdc.2019.07.001.

Article  PubMed  Google Scholar 

Olivieri I, Sarzi-Puttini P, Bugatti S, Atzeni F, d’Angelo S, Caporali R. Early treatment in early undifferentiated arthritis. Autoimmun Rev. 2012;11:589–92. https://doi.org/10.1016/j.autrev.2011.10.019.

Article  CAS  PubMed  Google Scholar 

Aletaha D, Maa JF, Chen S, Park SH, Nicholls D, Florentinus S, Furtner D, Smolen JS. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(12):1609–15.

Article  CAS  PubMed  Google Scholar 

Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40:2–e141. https://doi.org/10.1016/j.semarthrit.2010.03.003.

Article  PubMed  PubMed Central  Google Scholar 

Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, et al. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford). 2015;54:1074–9. https://doi.org/10.1093/rheumatology/keu446.

Article  CAS  PubMed  Google Scholar 

Egeberg A, Rosenø NAL, Aagaard D, Lørup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. https://doi.org/10.1016/j.semarthrit.2022.151979.

Article  CAS  PubMed  Google Scholar 

Calvo-Gutiérrez J, López-Medina C, Otero-Varela L, Escudero-Contreras A, Ortega-Castro R, Ladehesa-Pineda L, et al. Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry. Arthritis Res Ther. 2024;26:57. https://doi.org/10.1186/s13075-024-03287-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakellariou G, Scirè CA, Rumi F, Carrara G, Zanetti A, Cerra C, et al. Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases. Arthritis Res Ther. 2022;24(1):144. https://doi.org/10.1186/s13075-022-02824-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balduzzi S, Scirè CA, Sakellariou G, Benaglio F, Bugatti S, Montecucco C, et al. In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols. Clin Exp Rheumatol. 2017;35:401–5.

PubMed  Google Scholar 

Bugatti S, De Stefano L, Manzo A, Sakellariou G, Xoxi B, Montecucco C. Limiting factors to boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211011826. https://doi.org/10.1177/1759720X211011826.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24. https://doi.org/10.1002/art.1780310302.

Article  CAS  PubMed  Google Scholar 

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8. https://doi.org/10.1136/ard.2010.138461.

Article  PubMed  Google Scholar 

van der Heijde D. How to read radiographs according to the Sharp/van Der Heijde method. J Rheumatol. 1999;26:743–5.

PubMed  Google Scholar 

Hecquet S, Combier A, Steelandt A, Pons M, Wendling D, Molto A, et al. Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital. Rheumatology (Oxford). 2023;62:3866–74. https://doi.org/10.1093/rheumatology/kead143.

Article  CAS  PubMed  Google Scholar 

Haugeberg G, Hansen IJ, Soldal DM, Sokka T. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther. 2015;17:219. https://doi.org/10.1186/s13075-015-0716-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matthijssen XME, Niemantsverdriet E, Huizinga TWJ, van der Helm-van Mil AHM. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands. PLoS Med. 2020;17:e1003296. https://doi.org/10.1371/journal.pmed.1003296.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Combe B, Rincheval N, Berenbaum F, Boumier P, Cantagrel A, Dieude P, et al. Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology (Oxford). 2021;60:5073–9. https://doi.org/10.1093/rheumatology/keab398.

Article  CAS  PubMed